α-Adrenergic agonist. Prepn: H. Legerlotz, US 1932347 (1933 to Frederick Stearns); E. D. Bergmann, M. Sulzbacher, J. Org. Chem. 16, 84 (1951); M. K. Gurjar et al., Org. Process Res. Dev. 2, 422 (1998). Spectrophotometric determn: S. A. Shama, J. Pharm. Biomed. Anal. 30, 1385 (2002). Toxicity data: M. R. Warren, H. W. Werner, J. Pharmacol. Exp. Ther. 86, 284 (1946). Clinical efficacy in mydriasis: V. Tanner, A. G. Casswell, Eye 10, 95 (1996). Clinical evaluation in fecal incontinence: M. J. Cheetham et al., Gut 48, 356 (2001). Comprehensive description: C. A. Gaglia, Jr., Anal. Profiles Drug Subs. 3, 483-512 (1974). Review of ophthalmologic uses: S. M. Meyer, F. T. Fraunfelder, Ophthalmology 87, 1177-1180 (1980); of clinical trials vs ephedrine, q.v., in treatment of hypotension during cesarean delivery: A. Lee et al., Anesth. Analg. 94, 920-926 (2002).
Mydriatic; decongestant; in treatment of fecal incontinence.
α-Adrenergic Agonist; Decongestant; Mydriatic